Claudene J George1, Joe Verghese2. 1. Division of Geriatrics, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. Electronic address: Clgeorge@montefiore.org. 2. Division of Cognitive and Motor Aging and Geriatrics, Albert Einstein College of Medicine, Bronx, New York.
Abstract
OBJECTIVE: To examine the relationship between angiotensin-converting enzyme inhibitor (ACEI) use and gait performance in older adults. DESIGN: Cross-sectional survey. SETTING: Community. PARTICIPANTS: A total of 281 community-dwelling older adults with hypertension enrolled in an aging study. MEASUREMENTS: Quantitative variables used to define gait performance included velocity (cm/s), stride length (cm), swing time (s), stride length variability (SD), and swing time variability (SD). RESULTS: There were 72 hypertensive participants on ACEIs and 209 were on other antihypertensive medications. Linear regression analysis adjusted for age, sex, and potential confounders revealed that hypertensive participants on an ACEI walked 7.29 cm/s slower (P = .016) and stride length was 6.86 cm shorter (P = .006) compared with those not on ACEIs. There were no significant differences on the other gait variables examined. CONCLUSION: ACEI use was associated with worse gait performance in elderly hypertensives. Biological mechanisms need to be explored, and clinicians should consider monitoring gait speed in hypertensive patients on ACEIs.
OBJECTIVE: To examine the relationship between angiotensin-converting enzyme inhibitor (ACEI) use and gait performance in older adults. DESIGN: Cross-sectional survey. SETTING: Community. PARTICIPANTS: A total of 281 community-dwelling older adults with hypertension enrolled in an aging study. MEASUREMENTS: Quantitative variables used to define gait performance included velocity (cm/s), stride length (cm), swing time (s), stride length variability (SD), and swing time variability (SD). RESULTS: There were 72 hypertensiveparticipants on ACEIs and 209 were on other antihypertensive medications. Linear regression analysis adjusted for age, sex, and potential confounders revealed that hypertensiveparticipants on an ACEI walked 7.29 cm/s slower (P = .016) and stride length was 6.86 cm shorter (P = .006) compared with those not on ACEIs. There were no significant differences on the other gait variables examined. CONCLUSION: ACEI use was associated with worse gait performance in elderly hypertensives. Biological mechanisms need to be explored, and clinicians should consider monitoring gait speed in hypertensivepatients on ACEIs.
Authors: J E Galvin; C M Roe; K K Powlishta; M A Coats; S J Muich; E Grant; J P Miller; M Storandt; J C Morris Journal: Neurology Date: 2005-08-23 Impact factor: 9.910
Authors: Dawn E Alley; Gregory E Hicks; Michelle Shardell; William Hawkes; Ram Miller; Rebecca L Craik; Kathleen K Mangione; Denise Orwig; Marc Hochberg; Barbara Resnick; Jay Magaziner Journal: J Am Geriatr Soc Date: 2011-08-24 Impact factor: 5.562
Authors: Richard B Lipton; Mindy J Katz; Gail Kuslansky; Martin J Sliwinski; Walter F Stewart; Joe Verghese; Howard A Crystal; Herman Buschke Journal: J Am Geriatr Soc Date: 2003-10 Impact factor: 5.562